Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS).
As a biosimilar, Tyruko has the same safety and efficacy profile, mechanism of action, and pharmacological properties as Tysabri. Biosimilars are typically sold at lower prices than their reference medication, as generally occurs for generic medications.
Tyruko became available in Germany, Feb. 1, following its approval by the European Commision last year. Tyruko was developed by Polpharma Biologics, but is marketed by Sandoz, a subsidiary of Novartis that specializes in biosimilar medications.
“Early treatment with disease-modifying therapies can have a significant impact on people living with multiple sclerosis and their potential future disabilities. As the first and only biosimilar in this space, the availability of Tyruko is a crucial milestone in improving access to effective and safe therapies for those in Europe that need them most,” said Rebecca Guntern, president of Sandoz in Europe, in a company press release.
Read More, here: https://bit.ly/3HJoZ5X